Latest Insider Transactions at Exelixis, Inc. (EXEL)
This section provides a real-time view of insider transactions for Exelixis, Inc. (EXEL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of EXELIXIS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of EXELIXIS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 17
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+7.81%
|
$50,000
$1.7 P/Share
|
|
Feb 16
2021
|
Lance Willsey Director |
SELL
Open market or private sale
|
Direct |
50,000
-10.54%
|
$1,050,000
$21.9 P/Share
|
|
Feb 16
2021
|
Carl B Feldbaum Director |
SELL
Open market or private sale
|
Direct |
20,000
-70.12%
|
$420,000
$21.96 P/Share
|
|
Feb 16
2021
|
Carl B Feldbaum Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+41.22%
|
$60,000
$3.38 P/Share
|
|
Feb 15
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,718
-1.08%
|
$78,078
$21.91 P/Share
|
|
Feb 15
2021
|
Michael Morrissey President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,789
-1.72%
|
$205,569
$21.91 P/Share
|
|
Feb 15
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,858
-0.53%
|
$60,018
$21.91 P/Share
|
|
Feb 15
2021
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,685
-0.29%
|
$35,385
$21.91 P/Share
|
|
Feb 15
2021
|
Christopher J. Senner EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,105
-1.38%
|
$86,205
$21.91 P/Share
|
|
Feb 15
2021
|
Patrick J. Haley EVP, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
1,400
-0.57%
|
$29,400
$21.91 P/Share
|
|
Feb 12
2021
|
Patrick J. Haley EVP, Commercial |
SELL
Open market or private sale
|
Direct |
45,000
-15.42%
|
$945,000
$21.57 P/Share
|
|
Feb 03
2021
|
Christopher J. Senner EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
18,206
-5.78%
|
$400,532
$22.56 P/Share
|
|
Feb 03
2021
|
Christopher J. Senner EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
69,156
+9.78%
|
-
|
|
Feb 03
2021
|
Patrick J. Haley EVP, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
11,267
-3.72%
|
$247,874
$22.56 P/Share
|
|
Feb 03
2021
|
Patrick J. Haley EVP, Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
63,909
+9.1%
|
-
|
|
Feb 03
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
14,982
-2.68%
|
$329,604
$22.56 P/Share
|
|
Feb 03
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
BUY
Grant, award, or other acquisition
|
Direct |
81,038
+6.64%
|
-
|
|
Feb 03
2021
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
15,365
-2.53%
|
$338,030
$22.56 P/Share
|
|
Feb 03
2021
|
Jeffrey Hessekiel EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
64,409
+4.92%
|
-
|
|
Feb 03
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
19,997
-5.5%
|
$439,934
$22.56 P/Share
|
|
Feb 03
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
80,663
+9.75%
|
-
|
|
Feb 03
2021
|
Michael Morrissey President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
65,190
-10.28%
|
$1,434,180
$22.56 P/Share
|
|
Feb 03
2021
|
Michael Morrissey President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
23,238
+5.37%
|
-
|
|
Feb 01
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Open market or private sale
|
Direct |
65,000
-18.67%
|
$1,430,000
$22.08 P/Share
|
|
Feb 01
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
65,000
+15.73%
|
$65,000
$1.7 P/Share
|
|
Jan 12
2021
|
Christopher J. Senner EVP and CFO |
SELL
Open market or private sale
|
Direct |
30,000
-10.89%
|
$750,000
$25.0 P/Share
|
|
Jan 12
2021
|
Christopher J. Senner EVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+9.82%
|
$90,000
$3.66 P/Share
|
|
Jan 04
2021
|
Jeffrey Hessekiel EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+4.5%
|
$200,000
$4.59 P/Share
|
|
Jan 04
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Open market or private sale
|
Direct |
65,000
-18.67%
|
$1,300,000
$20.32 P/Share
|
|
Jan 04
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
65,000
+15.73%
|
$65,000
$1.7 P/Share
|
|
Dec 28
2020
|
Michael Morrissey President and CEO |
SELL
Bona fide gift
|
Indirect |
126,565
-11.31%
|
-
|
|
Dec 18
2020
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Open market or private sale
|
Direct |
65,000
-18.67%
|
$1,300,000
$20.01 P/Share
|
|
Dec 18
2020
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
65,000
+15.73%
|
$65,000
$1.7 P/Share
|
|
Dec 17
2020
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Bona fide gift
|
Direct |
2,500
-0.51%
|
-
|
|
Dec 04
2020
|
Lance Willsey Director |
BUY
Exercise of conversion of derivative security
|
Direct |
106,142
+18.28%
|
$530,710
$5.82 P/Share
|
|
Nov 24
2020
|
Vincent T Marchesi Director |
SELL
Open market or private sale
|
Direct |
40,004
-30.72%
|
$720,072
$18.5 P/Share
|
|
Nov 24
2020
|
Vincent T Marchesi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,004
+23.5%
|
$200,020
$5.82 P/Share
|
|
Nov 20
2020
|
Michael Morrissey President and CEO |
BUY
Bona fide gift
|
Indirect |
187,239
+14.34%
|
-
|
|
Nov 20
2020
|
Michael Morrissey President and CEO |
SELL
Bona fide gift
|
Direct |
187,239
-32.63%
|
-
|
|
Nov 15
2020
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
14,953
-1.02%
|
$299,060
$20.16 P/Share
|
|
Nov 15
2020
|
Jeffrey Hessekiel EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+5.72%
|
$210,000
$7.27 P/Share
|
|
Nov 15
2020
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
10,261
-0.72%
|
$205,220
$20.16 P/Share
|
|
Nov 15
2020
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,311
-1.29%
|
$226,220
$20.16 P/Share
|
|
Nov 15
2020
|
Christopher J. Senner EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,597
-1.77%
|
$271,940
$20.16 P/Share
|
|
Nov 15
2020
|
Patrick J. Haley EVP, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
10,446
-1.41%
|
$208,920
$20.16 P/Share
|
|
Nov 15
2020
|
Michael Morrissey President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
24,954
-1.41%
|
$499,080
$20.16 P/Share
|
|
Nov 10
2020
|
Jack L Wyszomierski Director |
SELL
Open market or private sale
|
Direct |
34,000
-14.67%
|
$680,000
$20.61 P/Share
|
|
Nov 10
2020
|
Jack L Wyszomierski Director |
BUY
Exercise of conversion of derivative security
|
Direct |
62,403
+21.21%
|
$312,015
$5.82 P/Share
|
|
Oct 22
2020
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
53,022
-15.26%
|
$1,113,462
$21.79 P/Share
|
|
Oct 22
2020
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
213,879
+38.1%
|
-
|